Mirum Pharmaceuticals (MIRM) to Release Quarterly Earnings on Wednesday

Key Points

• Mirum Pharmaceuticals is expected to report its Q2 2025 earnings on August 6th, with analysts predicting an earnings loss of ($0.31) per share and revenue of $107.91 million.
• In its last reported quarter, the company posted a 61.2% increase in revenue year-over-year, surpassing analyst expectations with $111.59 million compared to the anticipated $98.47 million.
• The stock currently has a consensus rating of "Buy" from analysts, with a price target averaging $65.50.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $107.91 million for the quarter.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The company had revenue of $111.59 million during the quarter, compared to analysts' expectations of $98.47 million. During the same period in the previous year, the firm posted ($0.54) earnings per share. The business's revenue for the quarter was up 61.2% compared to the same quarter last year. On average, analysts expect Mirum Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded up $0.34 on Friday, hitting $52.02. The company had a trading volume of 337,696 shares, compared to its average volume of 351,958. The company has a current ratio of 3.22, a quick ratio of 3.04 and a debt-to-equity ratio of 1.32. The company has a market cap of $2.58 billion, a PE ratio of -32.31 and a beta of 0.94. Mirum Pharmaceuticals has a 52-week low of $36.20 and a 52-week high of $54.78. The business has a 50 day moving average of $49.71 and a 200 day moving average of $46.88.

Insider Activity

In related news, SVP Jolanda Howe sold 564 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total value of $27,213.00. Following the transaction, the senior vice president directly owned 2,903 shares of the company's stock, valued at approximately $140,069.75. This trade represents a 16.27% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Mirum Pharmaceuticals by 102.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,518 shares of the company's stock worth $6,736,000 after purchasing an additional 75,630 shares during the period. AQR Capital Management LLC lifted its position in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company's stock valued at $2,211,000 after buying an additional 37,028 shares in the last quarter. Empowered Funds LLC lifted its position in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company's stock valued at $1,729,000 after buying an additional 5,120 shares in the last quarter. Intech Investment Management LLC lifted its position in Mirum Pharmaceuticals by 19.0% during the first quarter. Intech Investment Management LLC now owns 27,548 shares of the company's stock valued at $1,241,000 after buying an additional 4,398 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company's stock worth $1,176,000 after buying an additional 1,720 shares during the period.

Analysts Set New Price Targets

MIRM has been the topic of several analyst reports. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. JMP Securities raised their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Evercore ISI reaffirmed an "outperform" rating on shares of Mirum Pharmaceuticals in a research note on Friday, July 11th. HC Wainwright reiterated a "buy" rating and issued a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. Finally, Wall Street Zen cut Mirum Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, July 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $65.50.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.